Cargando…

139. The Morbidity and Financial Burden of Infective Endocarditis in Persons Who Inject Drugs in the Deep South

BACKGROUND: In the context of the opioid epidemic, infective endocarditis (IE) poses an economic challenge in Alabama. The objective of this proposal is to analyze the outcomes and financial burden of IE in persons who inject drugs (PWID) at The University of Alabama at Birmingham (UAB) Hospital, th...

Descripción completa

Detalles Bibliográficos
Autores principales: deMontigny, Danielle, Lee, Rachael A, Radney, Joshua, Eaton, Ellen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6810565/
http://dx.doi.org/10.1093/ofid/ofz360.214
_version_ 1783462286149550080
author deMontigny, Danielle
Lee, Rachael A
Radney, Joshua
Eaton, Ellen
author_facet deMontigny, Danielle
Lee, Rachael A
Radney, Joshua
Eaton, Ellen
author_sort deMontigny, Danielle
collection PubMed
description BACKGROUND: In the context of the opioid epidemic, infective endocarditis (IE) poses an economic challenge in Alabama. The objective of this proposal is to analyze the outcomes and financial burden of IE in persons who inject drugs (PWID) at The University of Alabama at Birmingham (UAB) Hospital, the largest tertiary referral center in this rural, Southern state. We hypothesized that those with the most severe substance use disorder would be most costly. METHODS: This is a retrospective study of PWID receiving care for IE at UAB Hospital from October 1, 2016 to March 1, 2019. IE was defined by Infectious Diseases consultation. Clinical data were obtained from the electronic medical record (EMR). Deaths were obtained from both the EMR and the regional medical examiner. Hospital costs (direct costs, overall charges) were obtained from financial accounts. To stratify patients by severity of substance use disorder, we used a 9-item risk assessment for PWID (see table). We then evaluated the association between clinical factors and outcomes (death, cost) using parametric and nonparametric tests when appropriate. A P-value < 0.05 was considered significant. RESULTS: A total of 69 persons met criteria (Table 1). The average length of stay was 30.8 days. Thirty-four (52%) had documentation of antibiotic completion (in or outpatient). Seventeen received surgery: 16 with valve replacement and one device removal. Overall, 14 (20%) died over the study period. There was no significant association between antibiotic completion or 9-item risk and death. When stratified into low risk (<4 items) vs. high risk (≥5), there was no difference in overall direct costs, LOS, or whether patients received surgery. CONCLUSION: PWID with IE at a hospital serving a rural, Southern population have a greater length of stay, discharges against advice, surgical interventions, and costs than other regions, relative to existing literature. The lack of association between 9-item risk and outcomes suggests that death and high costs are attributable to factors beyond substance use. Costs of providing care for this population are exorbitant and likely devastating for rural county hospitals within the context of the current public health and payment framework, including Medicaid non-expansion. [Image: see text] [Image: see text] [Image: see text] [Image: see text] DISCLOSURES: All authors: No reported disclosures.
format Online
Article
Text
id pubmed-6810565
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-68105652019-10-28 139. The Morbidity and Financial Burden of Infective Endocarditis in Persons Who Inject Drugs in the Deep South deMontigny, Danielle Lee, Rachael A Radney, Joshua Eaton, Ellen Open Forum Infect Dis Abstracts BACKGROUND: In the context of the opioid epidemic, infective endocarditis (IE) poses an economic challenge in Alabama. The objective of this proposal is to analyze the outcomes and financial burden of IE in persons who inject drugs (PWID) at The University of Alabama at Birmingham (UAB) Hospital, the largest tertiary referral center in this rural, Southern state. We hypothesized that those with the most severe substance use disorder would be most costly. METHODS: This is a retrospective study of PWID receiving care for IE at UAB Hospital from October 1, 2016 to March 1, 2019. IE was defined by Infectious Diseases consultation. Clinical data were obtained from the electronic medical record (EMR). Deaths were obtained from both the EMR and the regional medical examiner. Hospital costs (direct costs, overall charges) were obtained from financial accounts. To stratify patients by severity of substance use disorder, we used a 9-item risk assessment for PWID (see table). We then evaluated the association between clinical factors and outcomes (death, cost) using parametric and nonparametric tests when appropriate. A P-value < 0.05 was considered significant. RESULTS: A total of 69 persons met criteria (Table 1). The average length of stay was 30.8 days. Thirty-four (52%) had documentation of antibiotic completion (in or outpatient). Seventeen received surgery: 16 with valve replacement and one device removal. Overall, 14 (20%) died over the study period. There was no significant association between antibiotic completion or 9-item risk and death. When stratified into low risk (<4 items) vs. high risk (≥5), there was no difference in overall direct costs, LOS, or whether patients received surgery. CONCLUSION: PWID with IE at a hospital serving a rural, Southern population have a greater length of stay, discharges against advice, surgical interventions, and costs than other regions, relative to existing literature. The lack of association between 9-item risk and outcomes suggests that death and high costs are attributable to factors beyond substance use. Costs of providing care for this population are exorbitant and likely devastating for rural county hospitals within the context of the current public health and payment framework, including Medicaid non-expansion. [Image: see text] [Image: see text] [Image: see text] [Image: see text] DISCLOSURES: All authors: No reported disclosures. Oxford University Press 2019-10-23 /pmc/articles/PMC6810565/ http://dx.doi.org/10.1093/ofid/ofz360.214 Text en © The Author(s) 2019. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Abstracts
deMontigny, Danielle
Lee, Rachael A
Radney, Joshua
Eaton, Ellen
139. The Morbidity and Financial Burden of Infective Endocarditis in Persons Who Inject Drugs in the Deep South
title 139. The Morbidity and Financial Burden of Infective Endocarditis in Persons Who Inject Drugs in the Deep South
title_full 139. The Morbidity and Financial Burden of Infective Endocarditis in Persons Who Inject Drugs in the Deep South
title_fullStr 139. The Morbidity and Financial Burden of Infective Endocarditis in Persons Who Inject Drugs in the Deep South
title_full_unstemmed 139. The Morbidity and Financial Burden of Infective Endocarditis in Persons Who Inject Drugs in the Deep South
title_short 139. The Morbidity and Financial Burden of Infective Endocarditis in Persons Who Inject Drugs in the Deep South
title_sort 139. the morbidity and financial burden of infective endocarditis in persons who inject drugs in the deep south
topic Abstracts
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6810565/
http://dx.doi.org/10.1093/ofid/ofz360.214
work_keys_str_mv AT demontignydanielle 139themorbidityandfinancialburdenofinfectiveendocarditisinpersonswhoinjectdrugsinthedeepsouth
AT leerachaela 139themorbidityandfinancialburdenofinfectiveendocarditisinpersonswhoinjectdrugsinthedeepsouth
AT radneyjoshua 139themorbidityandfinancialburdenofinfectiveendocarditisinpersonswhoinjectdrugsinthedeepsouth
AT eatonellen 139themorbidityandfinancialburdenofinfectiveendocarditisinpersonswhoinjectdrugsinthedeepsouth